Fresenius Kabi, an operating company of Fresenius, has announced that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL).

Capsa Healthcare has introduced RoboPharma, powered by Axona, an integrated automation and enterprise software platform designed to support centralised pharmacy operations, including

AbCellera has entered into a collaboration with Vertex Pharmaceuticals to discover, develop, manufacture and commercialise multispecific T-cell engagers (TCEs) for the treatment of autoimmune

DKSH Healthcare has expanded its strategic partnership with Novartis in South Korea by adding the hypertension medicines Diovan® and Exforge® to its prescription drug portfolio. Under the agreement

Argenx has entered into a definitive agreement to acquire Forte Biosciences in an all-cash transaction valued at approximately US$2.2 billion.

Bora Pharmaceuticals and Onconic Therapeutics have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO, a potassium-competitive acid blocker (P-CAB)

Dassault Systèmes has signed a definitive agreement to acquire ArisGlobal in a deal valued at approximately US$1.8 billion in cash, with up to an additional US$200 million linked to multi-year AI-related revenue milestones.

Restore Vision has entered into a development and manufacturing partnership with Forge Biologics to support the advancement of RV-001, its investigational adeno-associated virus (AAV) gene therapy

Samsung Biologics has announced an all-cash public tender offer to acquire 100% of the share capital of PolyPeptide Group AG, a global contract development and manufacturing organisation (CDMO) specialising in peptide

Excalipoint Therapeutics has entered into a strategic partnership with DP Technology to co-develop a proprietary artificial intelligence (AI)-powered platform for the discovery of T-cell engagers (TCEs) and multi-specific antibodies.